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Objective: We sought to determine associations of total, cognitive/affective, and somatic 
depressive symptoms and antidepressant use with biomarkers of processes implicated in 
cardiovascular disease in HIV (HIV-CVD). 
 
Methods: We examined data from 1,546 HIV-positive and 843 HIV-negative veterans. 
Depressive symptoms were assessed using the Patient Health Questionnaire-9, and past-year 
antidepressant use was determined from VA pharmacy records. Monocyte (soluble CD14; 
sCD14), inflammatory (interleukin-6; IL-6), and coagulation (D-dimer) marker levels were 
determined from previously banked blood specimens. Linear regression models with multiple 
imputation were run to estimate associations between depression-related factors and CVD-
relevant biomarkers. 
 
Results: Among HIV-positive participants, greater somatic depressive symptoms were 
associated with higher sCD14 (exp[b]=1.02, 95% CI: 1.00-1.03) and D-dimer (exp[b]=1.06, 95% 
CI: 1.00-1.11) after adjustment for demographics and potential confounders. Further adjustment 
for antidepressant use and HIV factors slightly attenuated these relationships. Associations were 
also detected for antidepressant use, as selective serotonin reuptake inhibitor use was related to 
lower sCD14 (exp[b]=0.95, 95% CI: 0.91-1.00) and IL-6 (exp[b]=0.86, 95% CI: 0.76-0.96), and 
tricyclic antidepressant use was related to higher sCD14 (exp[b]=1.07, 95% CI: 1.03-1.12) and 
IL-6 (exp[b]=1.14, 95% CI: 1.02-1.28). Among HIV-negative participants, total, 
cognitive/affective, and somatic depressive symptoms were associated with higher IL-6, and 
tricyclic antidepressant use was related to higher sCD14. 






Conclusions: Our novel findings suggest that (a) monocyte activation and altered coagulation 
may represent two pathways through which depression increases HIV-CVD risk and that (b) 
tricyclic antidepressants may elevate and selective serotonin reuptake inhibitors may attenuate 
HIV-CVD risk by influencing monocyte and inflammatory activation. 
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Acronyms: ART = antiretroviral therapy; AUDIT-C = Alcohol Use Disorders Identification 
Test; CI = confidence interval; CV = coefficients of variability; CVD = cardiovascular disease; 
eGFR = estimated glomerular filtration rate; HDL = high-density lipoprotein; HIV = human 
immunodeficiency virus; ICD-9 = International Classification of Diseases, Ninth Revision; IL-6 
= interleukin-6; LDL = low-density lipoprotein; NNRTI = nonnucleoside reverse-transcriptase 
inhibitors; NRTI = nucleoside reverse-transcriptase inhibitors; PHQ-9 = Patient Health 
Questionnaire-9; PI = protease inhibitors; sCD14 = soluble CD14; SD = standard deviation; 
SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; VA = Veterans 
Affair; VACS = Veterans Aging Cohort Study. 
 
  







Highly-effective antiretroviral therapy (ART) has changed human immunodeficiency 
virus (HIV) from a life-threatening disease to a chronic disease requiring life-long management. 
However, with this transformation has come new health concerns. Chief among them is the high 
morbidity and mortality due to cardiovascular disease in HIV (HIV-CVD) (1). HIV-positive 
adults, versus HIV-negative adults, have a two-fold greater risk of developing CVD (1), and this 
elevated risk is not fully explained by established CVD risk factors or HIV factors (2). These 
observations have stimulated a search for novel risk factors for HIV-CVD that could serve as 
targets of future CVD prevention efforts.  
 
One such emerging risk factor for HIV-CVD is depression, which consists of cognitive, 
affective, and somatic symptoms. Depression is common in HIV – it has an estimated prevalence 
of 40-42%, although rates vary widely across studies (3). Furthermore, consistent with the 
substantial literature linking depression with future CVD in non-HIV samples (4), our group 
recently reported that depressive disorders are independently associated with incident acute 
myocardial infraction (5) and heart failure (6) in people with HIV. 
 
While the mechanisms underlying the depression to HIV-CVD relationship have yet to be 
elucidated, immune activation, systemic inflammation, and altered coagulation are strong 
candidates. First, all three processes play prominent roles in current conceptual frameworks of 
the pathogenesis of HIV-CVD, with HIV-related immune activation and the consequent systemic 
inflammation and altered coagulation contributing to atherosclerosis and clinical CVD onset (7). 
One indicator of immune activation is soluble CD14 (sCD14), which is considered a nonspecific 






marker of monocyte activation (8) and an acute phase protein (9). Second, immune activation, 
inflammatory, and coagulation markers – including sCD14, interleukin-6 (IL-6), and D-dimer, 
respectively – have been linked with both subclinical and clinical CVD in people with HIV (10-
12). To illustrate, in the Strategies for Management of Antiretroviral Therapy (SMART) study, 
each standard deviation (SD) increase in IL-6 and D-dimer was associated with a 39% and 40% 
increased risk of a CVD event, independent of CVD risk factors (13). Third, initial evidence 
suggests that, in HIV-positive adults, depression may be associated with elevated immune 
activation (14-19) and inflammatory (19-24) markers. Although these depression-biomarker 
studies report novel and potentially significant findings, they utilized small samples, did not 
include an HIV-negative group, had limited adjustment for potential confounders, and/or did not 
examine depressive symptom clusters or antidepressant medication use. 
 
Accordingly, our objective was to determine the independent associations of total 
depressive symptoms, cognitive/affective and somatic symptom clusters, and antidepressant use 
(regardless of treatment indication) with monocyte activation (sCD14), inflammatory (IL-6), and 
coagulation (D-dimer) markers in people living with HIV. While we hypothesized that greater 
total depressive symptoms would be related to higher and antidepressant use would be related to 
lower biomarker levels, we did not have hypotheses regarding depressive symptom clusters or 
antidepressant classes due to the paucity of evidence in HIV. However, a growing literature of 
non-HIV studies suggests that the somatic symptom cluster is more consistently associated with 
inflammatory markers than are the other clusters (see (25) for recent review), and a meta-
analysis of non-HIV studies indicates that treatment with selective serotonin reuptake inhibitors 
(SSRIs), but not with other antidepressant classes, may reduce inflammatory markers (26). 






Moreover, in the lone study examining depressive symptom subtypes and inflammatory markers 
in HIV, the group with severe/moderate somatic symptoms had elevated IL-6 (22). To achieve 
our objective, we examined data from the Biomarker Cohort of the Veterans Aging Cohort Study 
(VACS), which consists of 1,546 HIV-positive and 843 HIV-negative veterans. Inclusion of the 
HIV-negative group allowed us to assess whether HIV modifies associations between 
depression-related variables and CVD-relevant biomarkers. 
 
Material and Methods 
Participants 
Data came from the VACS Biomarker Cohort – a subset of participants from the parent 
VACS-9 study. VACS-9 is a prospective, multisite, cohort study of HIV-positive veterans and 
age, sex, race/ethnicity, and clinical site-matched HIV-negative veterans from nine Veterans 
Affair (VA) medical centers across the U.S. (27). The Biomarker Cohort consists of a subset of 
VACS-9 participants (n = 2,389) who consented to provide a blood sample at one time point 
between 2005-2006 (28). The matching procedures were not reapplied to the Biomarker Cohort. 
 
Measures 
Depressive Symptoms. In the parent VACS-9 study, the Patient Health Questionnaire-9 
(PHQ-9) (29) was administered multiple times to assess depressive symptoms over the last two 
weeks. The available studies suggest that the PHQ-9 is a reliable and valid instrument in people 
with HIV (30). For the present analysis, we used data from the PHQ-9 administration closest to 
the blood draw date (median [25th-75th percentile] = 31 [0-231] days prior to blood draw). PHQ-9 
total scores range from 0-27, with ≥10 being indicative of clinically significant depressive 






symptoms (31). In addition to the total score (sum of all nine items), we computed the 
cognitive/affective score as the sum of items 1 (anhedonia), 2 (depressed mood), 6 (low self-
esteem), 7 (concentration problems), 8 (psychomotor retardation/agitation), and 9 (suicidal 
ideation) and the somatic score as the sum of items 3 (sleep disturbance), 4 (fatigue), and 5 
(appetite changes). The PHQ-9 has high internal consistency and good sensitivity and specificity 
for identifying cases of major depressive disorder (29, 31). The cognitive/affective and somatic 
symptom clusters have been validated across major sociodemographic groups in a recent study 
utilizing a large, nationally representative sample of U.S. adults (32). For participants who were 
missing data for one item (n=147), we imputed that value with the mean of the other eight items. 
The PHQ-9 scores were converted to z-scores prior to analysis so that a 1-unit change 
corresponded to a 1-SD change. 
 
Antidepressant Use. Antidepressant use was defined as documentation of a filled 
prescription for an antidepressant medication up to 365 days before the blood draw date in the 
VA pharmacy records data. Separate yes/no variables were computed for following 
antidepressant classes: selective serotonin reuptake inhibitor (SSRI), tricyclic antidepressant 
(TCA), and miscellaneous other antidepressant. Medications from the following classes were 
coded as miscellaneous other: monoamine oxidase inhibitor, serotonin-norepinephrine reuptake 
inhibitor, serotonin antagonist and reuptake inhibitor, norepinephrine reuptake inhibitor, 
norepinephrine-dopamine reuptake inhibitor, and tetracyclic antidepressant. The treatment 
indication for the detected antidepressant use is not known. Of note, the indication for SSRIs and 
certain medications in our miscellaneous category (e.g., serotonin-norepinephrine reuptake 






inhibitors) is often a depressive disorder, whereas the indication for TCAs and other medications 
in our miscellaneous category (e.g., trazodone) is often insomnia or pain conditions (33). 
 
Monocyte Activation, Inflammatory, and Coagulation Markers. As is described 
elsewhere (28, 34), blood samples were collected at one time point between 2005-2006 using 
serum separator and EDTA tubes and were shipped to a central repository at the Massachusetts 
Veterans Epidemiology Research and Information Center. Assays for biomarkers examined here 
were conducted at the Laboratory for Clinical Biochemistry Research at the University of 
Vermont and used four controls per sample to assess interassay coefficients of variability (CVs). 
sCD14 was quantified by an enzyme-linked immunosorbent assay (Quantikine sCD14 
Immunoassay, R&D Systems, Minneapolis, MN) with a detectable range of 40-3,200 ng/ml. The 
interassay CVs ranged from 7.2-8.1%. IL-6 was quantified by a chemiluminescent immunoassay 
(QuantiGlo IL-6 immunoassay, R&D Systems, Minneapolis, MN) with detectable range of 0.4-
10,000 pg/mL. The interassay CVs ranged from 7.7-12.3%. D-dimer was quantified by a STAR 
automated coagulation analyzer (Diagnostica Stago, Parsippany, NJ) using an 
immunoturbidometric assay (Liatest D-DI) with a detectable range of 0.01-20 ug/mL. The 
interassay CVs ranged from 2.8-14.8%. All three biomarkers were natural log transformed 
before analysis to approximate a normal distribution. 
 
Covariates. As in our past work (28), covariate data were obtained closest to the blood 
draw date (see Table 1 for the coding of variables). Demographic factors were age, sex, and 
race/ethnicity. Several biomedical and behavioral factors were included in our models as 
covariates. CVD was identified by an International Classification of Diseases, Ninth Revision 






(ICD-9) code for acute myocardial infarction, unstable angina, cardiovascular revascularization, 
ischemic stroke, hemorrhagic stroke, heart failure, or cardiomyopathy before the blood draw 
date. Diabetes was defined by a previously validated metric using glucose values, diabetes 
medication use, and/or at least one inpatient or two outpatient ICD-9 codes for diabetes (35). 
Blood pressure was computed as the average of the three routine outpatient measurements 
obtained closest to the blood draw date. Hypertension was identified by blood pressure 
≥140/90 mmHg or documentation of antihypertensive medication. Low-density lipoprotein 
(LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride levels were 
obtained from the VA Corporate Data Warehouse. Statin use was defined by a filled prescription 
receipt for a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor. Hepatitis C infection 
was identified by a positive hepatitis C virus antibody test or at least one inpatient or two 
outpatient ICD-9 codes for hepatitis C infection. Estimated glomerular filtration rate (eGFR; a 
renal function indicator) and hemoglobin were defined by laboratory values extracted from the 
VA Corporate Data Warehouse. Body mass index and smoking were determined from the VA 
Health Factors dataset (36). The Alcohol Use Disorders Identification Test (AUDIT-C) (37) and 
alcohol abuse/dependence ICD-9 codes were used to create a 4-level alcohol use variable: not 
current, not hazardous (AUDIT-C <4), hazardous or heavy episodic (AUDIT-C ≥4), 
abuse/dependence (ICD-9 code). Cocaine abuse/dependence was identified by an ICD-9 code for 
a cocaine use disorder before the blood draw date. We included these substance use variables, as 
they have been associated with both depression and the biomarkers (28, 38, 39) and, thus, could 
confound the associations of interest. 
 






HIV factors were CD4+ T-cell count, HIV-1 RNA level, and ART use. CD4+ T-cell count 
and HIV-1 RNA level, measured as part of routine clinical care, were determined from VA 
Corporate Data Warehouse data obtained closest to the blood draw date (up to 180 days after). 
ART use was determined from VA pharmacy data for the timeframe 180 days prior to 7 days 
after the blood draw date and included the following classes: nucleoside reverse-transcriptase 




Participant characteristics were stratified by depression status separately for veterans with 
and without HIV (see Table 1). Independent samples t tests or Wilcoxon rank-sum tests for 
continuous variables and chi-square tests for categorical variables were used to assess for 
differences in participant characteristics by depression status. For these tests, the biomarker 
variables were examined in their original scale. 
 
Linear regression models were run to estimate the associations of total, 
cognitive/affective, and somatic depressive symptoms and antidepressant use with monocyte 
activation, inflammatory, and coagulation markers separately in veterans with and without HIV. 
Multiple imputations with five imputed datasets were generated using the "mi impute chained" 
command in Stata. Models were fitted in each imputed dataset and combined using Rubin’s rule 
to obtain pooled regression coefficients and standard errors.   
 






For each outcome variable (log transformed sCD14, IL-6, and D-dimer), we constructed 
four models. Model 1 adjusted for demographics (age, sex, and race/ethnicity). Model 2 was our 
primary model and further adjusted for the following biomedical and behavioral factors that 
could confound associations between depression-related variables and the biomarkers: CVD, 
diabetes, hypertension, LDL cholesterol, HDL cholesterol, triglycerides, statin use, hepatitis C 
infection, renal function, hemoglobin, BMI, smoking, alcohol use, and cocaine 
abuse/dependence. Model 3 added the three antidepressant use variables (past-year SSRI, TCA, 
and other antidepressant use) to Model 2. Model 4 added the HIV factors (CD4+ T-cell count, 
HIV-1 RNA level, and ART use) to Model 3. Separate models were run for each PHQ-9 variable 
(z-scored total, cognitive/affective, and somatic scores). Models 1-3 were also run in HIV-
negative veterans. Finally, the HIV x PHQ-9 total score, HIV x PHQ-9 cognitive/affective score, 
and HIV x PHQ-9 somatic score interactions were tested separately in Model 2’s that included 
the HIV main effect and involved entire cohort. Similarly, the HIV x SSRI use, HIV x TCA use, 
HIV x other antidepressant use interactions were tested simultaneously in a Model 3 that 
included the HIV main effect and involved entire cohort. 
 
Because our outcome variables were log transformed, we present the exponentiated 
regression coefficient [exp(b)] and its 95% confidence interval (CI) for each association. For 
continuous z-scored exposure variables (PHQ-9 variables), we computed the percent change in 
each biomarker per one-unit (i.e., 1-SD) change in each PHQ-9 variable using the following 
equation: [exp(b) – 1] x 100. For dichotomous exposure variables (antidepressant use variables), 
we used the same equation to compute the percent change in each biomarker per one-unit change 
(i.e., switching from “no” to “yes”) in each antidepressant use variable. 







Characteristics of Veterans in the VACS Biomarker Cohort 
Table 1 presents descriptive statistics for the biomarkers, depression variables, and 
covariates stratified by depression status (PHQ-9 total score ≥10: depressed, <10: not depressed,) 
separately for veterans with and without HIV. Of note, the SDs for the PHQ-9 total, 
cognitive/affective, and somatic scores were 6.6, 4.3, and 2.7 for the HIV-positive participants 
and 7.1, 4.7, and 2.9 for the HIV-negative participants. 
 
Among the HIV-positive participants, sCD14 was higher in the depressed group, but 
significant group differences were not detected for IL-6 or D-dimer. As was expected, the PHQ-9 
scores and antidepressant use rates were all higher in the depressed group. Significant differences 
in covariates were also observed, with the depressed group having higher levels/rates for 
hepatitis C infection, smoking, alcohol use, cocaine abuse/dependence, and HIV-1 RNA and 
lower levels/rates for age, LDL cholesterol, statin use, and CD4+ T-cell count. 
 
Among the HIV-negative participants, IL-6 and all depression variables were higher in 
the depressed group. Significant group differences were not detected for sCD14 or D-dimer. The 
depressed group had higher levels/rates for diabetes, triglycerides, hepatitis C infection, 
smoking, and cocaine abuse/dependence and lower levels/rates for age and statin use. 
 
Depressive Symptoms, Antidepressant Use, and Monocyte Activation 
Among the HIV-positive participants (see Table 2), the PHQ-9 total, cognitive/affective, 
and somatic scores were all associated with higher sCD14 in Model 1 adjusting for demographic 






factors. The somatic score remained positively related to sCD14 in our primary model (Model 2) 
adjusting for several potential confounders, although the total and cognitive/affective scores did 
not. The exp(b) of 1.02 indicates that every 1-SD increase in the somatic score (2.7 points on a 0-
9 scale) was associated with a 2% increase in sCD14 on average [(1.02 – 1) x 100]. Model 3, 
which added the antidepressant use variables, revealed that SSRI use was negatively related and 
TCA use was positively related to sCD14. SSRI use (versus no use) was associated with a 5% 
decrease in sCD14 on average, whereas TCA use was associated with a 7% increase in sCD14 
on average. The somatic score remained positively related to sCD14 in Model 3. In Model 4 
further adjusting for HIV factors, the pattern of results was similar, although the associations for 
the somatic score and SSRI use were slightly attenuated. 
 
Among the HIV-negative participants (see Table 2), the PHQ-9 scores were not 
associated with sCD14 in Models 1 or 2. Model 3 showed that TCA use was positively related to 
sCD14, with TCA use being associated with a 6% increase in sCD14 on average. The total and 
cognitive/affective scores were negatively related to sCD14 in Model 3; however, these 
associations may be unreliable, as they were not observed in Models 1 or 2. 
 
The HIV x SSRI use interaction was significant (p = 0.023), indicating that the 
relationship between SSRI use and sCD14 was stronger among the HIV-positive (negative 
association) versus the HIV-negative (no association) participants. The interactions between HIV 
and PHQ-9 total score, cognitive/affective score, somatic score, TCA use, and other 
antidepressant use were not significant (all ps >0.18), demonstrating that these relationships did 
not differ by HIV status.  






Depressive Symptoms, Antidepressant Use, and Systemic Inflammation 
Among the HIV-positive participants (see Table 3), the PHQ-9 total and 
cognitive/affective scores were not related to IL-6 in Models 1 or 2. Although the somatic score 
was associated with higher IL-6 in Model 1, adjustment for potential confounders in Model 2 
eliminated this relationship. Model 3 revealed that SSRI use was associated with 14% decrease 
and TCA use was associated with 14% increase in IL-6 on average. Model 4 results were similar 
to those of Model 3. 
 
Among the HIV-negative participants (see Table 3), the PHQ-9 total, cognitive/affective, 
and somatic scores were all associated with higher IL-6 in Models 1 and 2. In Model 2, every 1-
SD increase in the PHQ-9 total (7.1 points on a 0-27 scale), cognitive/affective (4.7 points on a 
0-18 scale), and somatic score (2.9 points on a 0-9 scale) was associated with a 8%, 7%, and 9% 
increase in IL-6 on average, respectively. In Model 3, the somatic score remained positively 
related to IL-6, although no antidepressant use variable was associated with IL-6. 
 
The interactions between HIV and PHQ-9 total score (p = 0.013), cognitive/affective 
score (p = 0.015), somatic score (p = 0.025), and SSRI use (p = 0.005) were significant. These 
results indicate that (a) relationships between the PHQ-9 scores and IL-6 were stronger among 
the HIV-negative (positive associations) versus the HIV-positive (no associations) participants 
and that (b) the relationship between SSRI use and IL-6 was stronger among the HIV-positive 
(negative association) versus the HIV-negative (no association) participants. The HIV x TCA use 
and HIV x other antidepressant use interactions were not significant (both ps >0.41). 
 






Depressive Symptoms, Antidepressant Use, and Altered Coagulation 
Among the HIV-positive participants (see Table 4), the PHQ-9 total, cognitive/affective, 
and somatic scores were all associated with higher D-dimer in Model 1. However, only the 
relationship with the somatic score remained significant in Model 2, with every 1-SD increase in 
that score (2.7 points on a 0-9 scale) being associated with a 6% increase in D-dimer on average. 
In Model 3, no antidepressant use variable was associated with D-dimer. The association for the 
PHQ-9 somatic score was slightly attenuated in Models 3 and 4, falling short of significance. 
 
 Among the HIV-negative participants (see Table 4), no PHQ-9 score or antidepressant 
use variable was associated with D-dimer across models. 
 
The interactions between HIV and PHQ-9 total score, cognitive/affective score, somatic 
score, SSRI use, TCA use, and other antidepressant use were all not significant (all ps >0.15).  
 
Discussion 
 We report novel independent associations between depression-related variables and 
monocyte activation, systemic inflammation, and altered coagulation – which are all implicated 
in HIV-CVD (7). In HIV-positive veterans, greater somatic depressive symptoms were related to 
higher sCD14 and D-dimer in our primary model adjusting for demographics and potential 
medical and behavioral confounders. Further adjustment for antidepressant use and HIV factors 
slightly attenuated these relationships. In addition, past-year SSRI use was linked to lower and 
past-year TCA use was linked to higher sCD14 and IL-6 in HIV-positive veterans. 






The observed relationships are small (2%-14% biomarker change), and their clinical 
relevance is unclear. Nevertheless, because we found relationships unlikely due to chance, our 
results raise the possibilities that (a) monocyte activation and altered coagulation may be two of 
the likely many mechanisms through which depressive symptoms may increase HIV-CVD risk 
and that (b) TCA treatment may elevate and SSRI treatment may attenuate HIV-CVD risk due to 
their possible effects on monocyte activation and systemic inflammation. Future prospective 
studies, ideally randomized controlled trials, are needed to rigorously evaluate these possibilities. 
 
Our study makes important contributions to the HIV literature examining relationships 
between depression-related factors and CVD-relevant biomarkers, as it has the largest sample to 
date, included an HIV-negative group, adjusted for several potential confounders, and examined 
depressive symptoms clusters and antidepressant use. HIV studies (14-19) have detected 
depression-immune activation associations, as we did here for sCD14. We extend those findings 
with evidence that the somatic symptoms may be contributing more to this link than the 
cognitive/affective symptoms. HIV studies have also reported depression-inflammation 
associations (19-24), conflicting with the lack of relationships for IL-6 here. Of relevance, 
Norcini Pala and colleagues (22) examined depressive symptom subtypes, observing elevated IL-
6 in the group with severe/moderate somatic symptoms. A possible explanation for these 
discrepant results is that our models included more extensive adjustment for potential 
confounders than most studies. Consistent with this idea, greater somatic symptoms were 
associated with higher IL-6 in our demographics-adjusted model but not in our subsequent 
models. To our knowledge, our study is the first to report a relationship between greater depressive 






symptoms and higher levels of a coagulation marker (D-dimer) in HIV. Our findings further 
suggest that this is another link to which the somatic symptoms may be contributing more than 
the cognitive/affective symptoms. 
 
There are five plausible, non-mutually exclusive explanations for the relationships we 
observed. One, elevated depressive symptoms could lead to immune activation and altered 
coagulation through the putative mechanisms underlying depression-immune function 
relationships, such as autonomic dysfunction, hypothalamic-pituitary-adrenal axis dysregulation, 
and increased adiposity (40, 41). In line with our stronger associations of the somatic cluster with 
sCD14 and D-dimer, others have found the somatic depressive symptoms to be more strongly 
related to autonomic dysfunction (42) and abdominal obesity (43) than the cognitive depressive 
symptoms. Two, depression has been associated with markers of increased gut permeability (44, 
45), which promotes immune activation due to increased microbial translocation from the gut to 
circulation (46). Three, a candidate behavioral mechanism specific to HIV is ART nonadherence, 
as depression is associated with poorer adherence to HIV treatment (47), with resulting poorer 
control of viremia-associated immune activation. Four, increased release of proinflammatory 
cytokines in the central nervous system – due, in part, to HIV-related immune activation – could 
produce elevated depressive symptoms, particularly the somatic symptoms (“sickness 
behavior”), via their effects on neurobiological systems implicated in depression (48-50). Five, 
confounders, such as HIV severity, could be contributing to the observed relationship, especially 
considering the overlap between somatic depressive symptoms and HIV symptoms (51). 
However, our primary models adjusted for several comorbid conditions, and further adjustment 
for viral load and CD4+ T-cell count only slightly attenuated associations. 






Although we are not aware of previous HIV studies examining relationships between 
antidepressant use and CVD-relevant biomarkers, meta-analytic evidence from non-HIV studies 
indicates that IL-6 decreases following SSRI, but not TCA, treatment (26). Furthermore, a 
systematic review of non-HIV studies concluded that both SSRIs and TCAs appear to reduce 
inflammatory markers (52). Those prior reviews are consistent with our finding that SSRI use is 
associated with lower immune activation (sCD14) and systemic inflammation (IL-6) in people 
with HIV. SSRIs may have direct immunomodulary effects or indirect effects through improved 
depression and HIV treatment adherence (53, 54). SSRIs may also have antimicrobial effects 
and, thus, may restore gut microbiota balance (55), thereby decreasing gut permeability and the 
consequent bacterial translocation, immune activation, and systemic inflammation. Those prior 
reviews, however, are inconsistent with our finding that TCA use is related to higher sCD14 and 
IL-6 levels. One possible explanation for this discrepancy is that TCA use is acting as a marker 
of treatment-resistant depression, as SSRIs are typically recommended as first-line 
antidepressants (56). Another possible explanation is that TCA use is acting as a proxy for 
conditions not in our models, as these medications are often prescribed for other conditions 
linked with immune/inflammatory activation, such as insomnia and chronic pain (33). 
 
We also observed noteworthy associations in HIV-negative veterans. First, we detected 
positive associations of total, cognitive/affective, and somatic depressive symptoms with IL-6. 
Second, we found that TCA use was linked to higher sCD14. Our findings are in line with a 
recent meta-analysis of non-HIV studies showing that depression is associated with higher 
inflammatory markers predictive of CVD (57). We also detected some differences in 
relationships by HIV status. SSRI use was more strongly associated with lower sCD14 and IL-6 






in HIV-positive veterans, raising the possibility that SSRI therapy (currently first-line 
antidepressants) may be a promising approach to reducing monocyte and inflammatory 
activation in depressed people with HIV. In addition, PHQ-9 scores were more strongly related 
to higher IL-6 in HIV-negative veterans. 
 
Some limitations deserve attention. First, our cross-sectional data prevents us from 
drawing inferences regarding directionality of associations, and both directions are plausible. 
More specifically, because the immune activation, inflammatory, and coagulation markers were 
assessed at only one time point in the VACS Biomarker Cohort, we could not examine 
associations between baseline depression variables and changes over time in these biomarkers. 
Second, our yes/no past-year antidepressant use variables lack precision, which could have led us 
to underestimate their true effect sizes. Incorporating dose, duration, and recency of use would 
provide a more nuanced assessment. In addition, we do not know the treatment indication for the 
detected antidepressant use. To illustrate, 28% of HIV-positive and HIV-negative veterans 
classified as not depressed had past-year antidepressant use – a group that likely consists of those 
whose prior depression had been successfully treated and those taking antidepressants for other 
indications, such as anxiety, insomnia, or pain conditions (33). Third, it is unknown whether our 
findings extend to women. The VACS Biomarker Cohort, especially the HIV-positive group, 
contains a low percentage of women, which may explain the observed lower prevalence of 
depression (23%) in veterans with HIV compared to prior estimates (3). 
 
In sum, our findings suggest that (a) monocyte activation and altered coagulation may be 
two pathways through which depression increases HIV-CVD risk and that (b) TCAs may elevate 






and SSRIs may attenuate HIV-CVD risk by influencing monocyte activation and systemic 
inflammation. Ultimately, elucidating the mechanisms underlying the depression to HIV-CVD 
association could identify additional targets (beyond depression itself) for novel HIV-CVD 
prevention efforts. Moreover, determining the effect of various classes of antidepressants on 
HIV-CVD risk and relevant biomarkers could lead to the development of antidepressant 
algorithms to simultaneously treat depression and lower CVD risk in people with HIV. 
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Soluble CD14, median (25th-75th 
percentile), ng/mL 
1822 (1511-2137) 1694 (1432-2073) 0.002 1757 (1491-2075) 1720 (1467-2032) 0.44 
Interleukin-6, median (25th-75th 
percentile), pg/mL 
2.20 (1.47-3.55) 2.03 (1.41-3.35) 0.14 2.10 (1.25-3.51) 1.73 (1.13-2.90) 0.013 
D-dimer, median (25th-75th  
percentile), μg/mL 
0.29 (0.16-0.53) 0.26 (0.15-0.48) 0.091 0.32 (0.21-0.53) 0.29 (0.21-0.53) 0.80 
Depression Variables 
PHQ-9 Total Score (0-27), mean (SD) 15.9 (5.2) 2.7 (2.9) <0.001 16.1 (4.9) 2.9 (2.9) <0.001 
PHQ-9 Cognitive/affective Score (0-18), 
mean (SD) 9.6 (4.1) 1.2 (1.8) <0.001 9.8 (3.7) 1.4 (1.8) <0.001 
PHQ-9 Somatic Score (0-9), mean (SD) 6.3 (2.1) 1.4 (1.6) <0.001 6.4 (2.1) 1.5 (1.6) <0.001 
Past-Year SSRI Use, n (%) 180 (52) 248 (21) <0.001 141 (54) 121 (21) <0.001 
Past-Year TCA Use, n (%) 82 (24) 139 (12) <0.001 69 (26) 64 (11) <0.001 
Past-Year Other Antidepressant Use,  
n (%) 162 (47) 227 (19) <0.001 138 (52) 122 (21) <0.001 
Covariates 
Age, mean (SD), years 51.1 (7.6) 51.9 (8.4) <0.001 52.0 (7.9) 54.2 (9.8) <0.001 
Women, n (%) 10 (3) 32 (3) 0.87 32 (12) 49 (9) 0.10 
Race/Ethnicity, n (%) 
     White 
     African American 
     Hispanic 






















Cardiovascular Disease, n (%) 75 (22) 204 (17) 0.071 72 (27) 158 (28) 0.96 
Diabetes, n (%) 67 (19) 234 (20) 0.81 93 (35) 154 (27) 0.012 
Hypertension, n (%) 90 (26) 272 (23) 0.29 72 (27) 157 (27) 0.97 
LDL Cholesterol, n (%) 
     <100 mg/dL 
     100-129 mg/dL 
     130-159 mg/dL 



























HDL Cholesterol, n (%) 
     ≥60 mg/dL 
     40-59 mg/dL 


















Triglycerides ≥150 mg/dL, n (%) 170 (49) 513 (44) 0.078 91 (35) 157 (28) 0.035 
Statin Use, n (%) 79 (23) 376 (32) 0.001 100 (38) 257 (45) 0.067 
Hepatitis C Infection, n (%) 209 (60) 510 (43) <0.001 98 (37) 164 (29) 0.012 
eGFR <60 ml/min/1.73 m2, n (%) 58 (10) 18 (7) 0.45 92 (8) 23 (7) 0.13 
Hemoglobin, n (%) 
     ≥14 g/dL 
     12.0-13.9 g/dL 


















Body Mass Index ≥30 kg/m2, n (%) 61 (18) 185 (16) 0.44 123 (47) 265 (46) 0.85 
Smoking, n (%) 
     Never 
     Past 


















Alcohol Use, n (%) 
Not Current 
Not Hazardous 























Cocaine Abuse/Dependence, n (%) 165 (47) 386 (33) <0.001 120 (46) 197 (34) 0.002 
CD4+ T-cell Count, n (%) 
     ≥500/mm3 
     200-499/mm3 









0.002 --- --- --- 
HIV-1 RNA Level ≥500 copies/mL, n (%) 150 (43) 366 (31) <0.001 --- --- --- 
Antiretroviral Therapy Use, n (%) 292 (84) 1004 (85) 0.57 --- --- --- 
Note. PHQ-9 total score ≥10: depressed, <10: not depressed. All variables had complete data except (n): IL-6 (2,342), sCD14 (2,354), D-dimer (2,349), PHQ-9 
total score (2,364), PHQ-9 cognitive/affective score (2,325), PHQ-9 somatic score (2,296), hypertension (2,385), LDL cholesterol (2,311), HDL cholesterol 
(2,319), triglycerides (2,349), eGFR (2,380), hemoglobin (2,385), body mass index (2,380), smoking (2,385), alcohol use (2,384), CD4+ T-cell count (1,542), 
and HIV-1 RNA level (1,542). HIV = human immunodeficiency virus. VACS = Veterans Aging Cohort Study. PHQ-9 = Patient Health Questionnaire-9. SSRI = 
selective serotonin reuptake inhibitor. TCA = tricyclic antidepressant. LDL = low-density lipoprotein. HDL = high-density lipoprotein. eGFR = estimated 
glomerular filtration rate. RNA = ribonucleic acid.





Table 2. Linear Regression Models Examining Associations of Depressive Symptoms and Antidepressant Use with Soluble CD14 
Separately among HIV-Positive and HIV-Negative Veterans in the VACS Biomarker Cohort 
 HIV-Positive (n=1,546) 
Model 1: Demographics-
Adjusted Modela 
Model 2 (Primary Model): 
Model 1 + Confoundersb 
Model 3: Model 2 +  
Antidepressants 
Model 4: Model 3 +  
HIV Factorsc 
exp(b) 95% CI exp(b) 95% CI exp(b) 95% CI exp(b) 95% CI 
PHQ-9 Total 1.02* 1.01-1.04 1.01† 1.00-1.03 1.01 1.00-1.03 1.01 0.99-1.02 
PHQ-9 Cognitive/affective 1.02* 1.00-1.03 1.01 0.99-1.02 1.01 0.99-1.02 1.00 0.99-1.02 
PHQ-9 Somatic 1.03* 1.01-1.04 1.02* 1.00-1.03 1.02*  1.00-1.03 1.01† 1.00-1.03 
SSRI Use  0.95* 0.91-1.00 0.96* 0.92-1.00 
TCA Use 1.07* 1.03-1.12 1.07* 1.02-1.11 
Other Antidepressant Use 1.04† 1.00-1.09 1.04† 1.00-1.09 
 HIV-Negative (n=843) 
PHQ-9 Total 1.01 0.99-1.02 0.99 0.98-1.01 0.98* 0.96-1.00  
PHQ-9 Cognitive/affective 1.00 0.99-1.02 0.99 0.97-1.01 0.98* 0.96-1.00 
PHQ-9 Somatic 1.01 0.99-1.03 1.00 0.98-1.01 0.99 0.97-1.00 
SSRI Use  1.04† 0.99-1.10 
TCA Use 1.06* 1.00-1.11 
Other Antidepressant Use 1.01 0.96-1.07 
Note. Soluble CD14 is log transformed. PHQ-9 variables are z scored. Statistically significant effects are bolded. HIV = human immunodeficiency virus. VACS 
= Veterans Aging Cohort Study. exp(b) = exponentiated regression coefficient. CI = confidence interval. PHQ-9 = Patient Health Questionnaire-9. SSRI = 
selective serotonin reuptake inhibitor. TCA = tricyclic antidepressant.  
aAdjusted for age, sex, and race/ethnicity. 
bAdditionally adjusted for cardiovascular disease, diabetes, hypertension, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, 
statin use, hepatitis C infection, renal function, hemoglobin, BMI, smoking, alcohol use, and cocaine abuse/dependence.  
cAdditionally adjusted for CD4+ T-cell count, HIV-1 RNA level, and ART use. 
*p < .05  
†p = .05-.10 





Table 3. Linear Regression Models Examining Associations of Depressive Symptoms and Antidepressant Use with Interleukin-6 





Model 2 (Primary Model): 
Model 1 + Confoundersb 
Model 3: Model 2 +  
Antidepressants 
Model 4: Model 3 +  
HIV Factorsc 
exp(b) 95% CI exp(b) 95% CI exp(b) 95% CI exp(b) 95% CI 
PHQ-9 Total 1.04† 1.00-1.08 1.00 0.96-1.04 1.00 0.96-1.04 0.99 0.95-1.02 
PHQ-9 Cognitive/affective 1.03 0.99-1.07 0.99 0.95-1.03 0.99 0.95-1.03 0.97 0.94-1.01 
PHQ-9 Somatic 1.06* 1.02-1.10 1.01 0.98-1.05 1.02 0.98-1.06 1.01 0.97-1.05 
SSRI Use  0.86* 0.76-0.96 0.86* 0.77-0.96 
TCA Use 1.14* 1.02-1.28 1.13* 1.01-1.27 
Other Antidepressant Use 1.12† 0.99-1.26 1.13† 1.00-1.27 
 
HIV-Negative (n=843) 
PHQ-9 Total 1.11* 1.05-1.18 1.08*  1.02-1.14 1.05† 0.99-1.12  
PHQ-9 Cognitive/affective 1.10* 1.04-1.16 1.07* 1.01-1.13 1.04 0.98-1.10 
PHQ-9 Somatic 1.13* 1.06-1.19 1.09* 1.03-1.15 1.06* 1.00-1.12 
SSRI Use  1.12 0.94-1.33 
TCA Use 1.05 0.88-1.24 
Other Antidepressant Use 1.07 0.90-1.27 
Note. Interleukin-6 is log transformed. PHQ-9 variables are z scored. Statistically significant effects are bolded. HIV = human immunodeficiency virus. VACS = 
Veterans Aging Cohort Study. exp(b) = exponentiated regression coefficient. CI = confidence interval. PHQ-9 = Patient Health Questionnaire-9. SSRI = selective 
serotonin reuptake inhibitor. TCA = tricyclic antidepressant.  
aAdjusted for age, sex, and race/ethnicity. 
bAdditionally adjusted for cardiovascular disease, diabetes, hypertension, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, 
statin use, hepatitis C infection, renal function, hemoglobin, BMI, smoking, alcohol use, and cocaine abuse/dependence.  
cAdditionally adjusted for CD4+ T-cell count, HIV-1 RNA level, and ART use. 
*p < .05  
†p = .05-.10 





Table 4. Linear Regression Models Examining Associations of Depressive Symptoms and Antidepressant Use with D-Dimer 





Model 2 (Primary Model): 
Model 1 + Confoundersb 
Model 3: Model 2 +  
Antidepressants 
Model 4: Model 3 +  
HIV Factorsc 
exp(b) 95% CI exp(b) 95% CI exp(b) 95% CI exp(b) 95% CI 
PHQ-9 Total 1.09* 1.03-1.15 1.05† 1.00-1.11 1.04 0.99-1.10 1.03 0.97-1.08 
PHQ-9 Cognitive/affective 1.07* 1.02-1.13 1.04 0.99-1.10 1.03 0.98-1.09 1.01 0.96-1.07 
PHQ-9 Somatic 1.10* 1.04-1.16 1.06* 1.00-1.11 1.05† 0.99-1.11 1.04  0.98-1.09 
SSRI Use  0.98 0.84-1.13 0.99 0.86-1.15 
TCA Use 0.97 0.84-1.13 0.98 0.84-1.13 
Other Antidepressant Use 1.14 0.97-1.33 1.15† 0.98-1.34 
 
HIV-Negative (n=843) 
PHQ-9 Total 1.02 0.96-1.07 1.01 1.00-1.02 1.00 0.94-1.06  
PHQ-9 Cognitive/affective 1.01 0.96-1.07 1.00 0.95-1.06 1.00 0.94-1.06 
PHQ-9 Somatic 1.02 0.96-1.08 1.00 0.95-1.06 1.00 0.94-1.06 
SSRI Use  1.09 0.92-1.29 
TCA Use 0.97 0.83-1.15 
Other Antidepressant Use 0.95 0.81-1.13 
Note. D-dimer is log transformed. PHQ-9 variables are z scored. Statistically significant effects are bolded. HIV = human immunodeficiency virus. VACS = 
Veterans Aging Cohort Study. exp(b) = exponentiated regression coefficient. CI = confidence interval. PHQ-9 = Patient Health Questionnaire-9. SSRI = selective 
serotonin reuptake inhibitor. TCA = tricyclic antidepressant.  
aAdjusted for age, sex, and race/ethnicity. 
bAdditionally adjusted for cardiovascular disease, diabetes, hypertension, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, 
statin use, hepatitis C infection, renal function, hemoglobin, BMI, smoking, alcohol use, and cocaine abuse/dependence.  
cAdditionally adjusted for CD4+ T-cell count, HIV-1 RNA level, and ART use. 
*p < .05  
†p = .05-.10 
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